One World Health

Announces the successful completion of phase3(b) clinical trials on PMIM, a treatment for isceral leishmaniasis (VL or kala-azar). It then outlines the methods used and gives an overview of the treatment and the disease.

PATH's Drug Development program has developed a new medication to treat diarrhea. This new drug treats the diarrheal process to shorten its duration.

Dr. Ponni Subbiah will join OneWorld Health on August 1st, 2012 as its first global program leader.

Dr. Geno deHostos, OneWorld Health's Director of Research and Preclinical Development, spoke at NIH about the important role product development partnershops play in creating new treatments for neglected tropical diseases.

Will be used to develop a new anti-diarrheal drug for use in the developing world

OWH will move forward with its partners on public health studies to help the government determine the best way to distribute and use the treatment in its public health system throughout the VL-endemic regions.

A safety and efficacy of an important study for a new treatment for the deadly visceral leishmaniasis (VL, kala-azar or black fever) moves forward.

The campaign is supported by an educational grant from Sanofi Pasteur in India

Will Focus on New Treatment Modalities for this Deadly Disease

OneWorld Health teams up with A-Cube to develop DNA Vaccines